CONSOLIDATED SCHEDULE OF INVESTMENTS £ in Thousands |
9 Months Ended |
12 Months Ended |
|
|
|
|
Sep. 30, 2022
USD ($)
shares
|
Dec. 31, 2021
USD ($)
shares
|
Sep. 30, 2022
GBP (£)
shares
|
Dec. 31, 2021
GBP (£)
shares
|
Sep. 30, 2021
USD ($)
|
Dec. 31, 2020
USD ($)
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 2,869,469,000
|
|
$ 2,390,984,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
2,825,738,000
|
|
2,434,522,000
|
|
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
150,539,000
|
[1] |
142,219,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
134,134,000
|
|
184,710,000
|
|
|
|
|
|
|
|
|
Warrant Investment |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
31,148,000
|
[1] |
27,147,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
27,159,000
|
|
38,399,000
|
|
|
|
|
|
|
|
|
Investments in Securities [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
|
|
2,388,952,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
|
|
2,432,708,000
|
|
|
|
|
|
|
|
|
Investment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
|
|
2,390,984,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
|
|
2,434,522,000
|
|
|
|
|
|
|
|
|
Investment Funds & Vehicles [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
3,139,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
3,046,000
|
|
|
|
|
|
|
|
|
|
|
Senior Secured |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
2,607,006,000
|
|
$ 2,156,709,000
|
|
|
|
|
|
|
|
|
Senior Secured | Blue Sprig Pediatrics, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment, Interest Rate, Paid in Kind |
|
|
|
4.45%
|
|
|
|
4.45%
|
|
|
|
|
Total Investments Before Cash And Cash Equivalent [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[3] |
2,869,469,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
2,825,738,000
|
|
|
|
|
|
|
|
|
|
|
Total Investments with Cash and Cash Equivalents |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[3] |
2,894,469,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[3] |
2,850,738,000
|
|
|
|
|
|
|
|
|
|
|
Total investments In Securities |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
2,866,330,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
2,822,692,000
|
|
|
|
|
|
|
|
|
|
|
Cash and Cash Equivalents | G S Financial Square Government Fund |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
25,000,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
25,000,000
|
|
|
|
|
|
|
|
|
|
|
Money Market Funds [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[3] |
25,000,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[3] |
25,000,000
|
|
|
|
|
|
|
|
|
|
|
Debt Investments |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
2,684,643,000
|
[1] |
$ 2,219,586,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
2,661,399,000
|
|
2,209,599,000
|
|
|
|
|
|
|
|
|
Unsecured |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
54,393,000
|
|
52,890,000
|
|
|
|
|
|
|
|
|
Communications & Networking |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
101,094,000
|
|
105,490,000
|
|
|
|
|
|
|
|
|
Communications & Networking | Equity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
|
|
1,230,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
|
|
6,260,000
|
|
|
|
|
|
|
|
|
Communications & Networking | Warrant Investment |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
541,000
|
[1] |
418,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
140,000
|
|
0
|
|
|
|
|
|
|
|
|
Communications & Networking | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
98,596,000
|
[1] |
97,088,000
|
[4] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
100,954,000
|
|
99,230,000
|
|
|
|
|
|
|
|
|
Communications & Networking | Aryaka Networks, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
123,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 140,000
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
Jun. 28, 2022
|
|
|
|
|
|
|
|
|
|
|
Shares | shares |
|
229,611
|
|
|
|
229,611
|
|
|
|
|
|
|
Communications & Networking | Peerless Network Holdings, Inc. | Equity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
|
|
1,230,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
|
|
$ 6,260,000
|
|
|
|
|
|
|
|
|
Shares | shares |
|
|
|
1,138,328
|
|
|
|
1,138,328
|
|
|
|
|
Communications & Networking | Peerless Network Holdings, Inc. | Equity | Preferred Series A |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
|
|
$ 1,230,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
|
|
$ 6,242,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[6] |
|
|
Apr. 11, 2008
|
|
|
|
|
|
|
|
|
Shares | shares |
|
|
|
1,135,000
|
|
|
|
1,135,000
|
|
|
|
|
Communications & Networking | Peerless Network Holdings, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
|
|
$ 0
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
|
|
$ 18,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[6] |
|
|
Oct. 21, 2020
|
|
|
|
|
|
|
|
|
Shares | shares |
|
|
|
3,328
|
|
|
|
3,328
|
|
|
|
|
Communications & Networking | Spring Mobile Solutions, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 418,000
|
[1] |
$ 418,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 0
|
|
$ 0
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Apr. 19, 2013
|
[5] |
Apr. 19, 2013
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
2,834,375
|
|
2,834,375
|
|
2,834,375
|
|
2,834,375
|
|
|
|
|
Communications & Networking | Senior Secured | Aryaka Networks, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-07
|
|
|
|
2026-07
|
|
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[7] |
3.25%
|
|
|
|
3.25%
|
|
|
|
|
|
|
Investment, Interest Rate, Floor |
[7] |
6.75%
|
|
|
|
6.75%
|
|
|
|
|
|
|
Investment, Interest Rate, Paid in Kind |
[7] |
1.05%
|
|
|
|
1.05%
|
|
|
|
|
|
|
Principal Amount |
[8],[9],[10] |
$ 5,009,000
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[8],[9],[10] |
4,943,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[8],[9],[10] |
$ 4,943,000
|
|
|
|
|
|
|
|
|
|
|
Communications & Networking | Senior Secured | Cytracom Holdings LLC | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-02
|
|
2025-02
|
|
2025-02
|
|
2025-02
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
9.31%
|
[7] |
9.31%
|
[11] |
9.31%
|
[7] |
9.31%
|
[11] |
|
|
|
Investment, Interest Rate, Floor |
|
10.31%
|
[7] |
10.31%
|
[11] |
10.31%
|
[7] |
10.31%
|
[11] |
|
|
|
Principal Amount |
|
$ 8,933,000
|
[10],[12],[13] |
$ 9,000,000
|
[14],[15],[16] |
|
|
|
|
|
|
|
Investment cost |
|
8,776,000
|
[1],[10],[12],[13] |
8,802,000
|
[4],[14],[15],[16] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 8,728,000
|
[10],[12],[13] |
$ 8,725,000
|
[14],[15],[16] |
|
|
|
|
|
|
|
Communications & Networking | Senior Secured | Rocket Lab Global Services, LLC | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-06
|
|
2024-06
|
|
2024-06
|
|
2024-06
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
3.25%
|
|
|
|
3.25%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
4.90%
|
[7] |
4.90%
|
[11] |
4.90%
|
[7] |
4.90%
|
[11] |
|
|
|
Investment, Interest Rate, Floor |
|
8.15%
|
[7] |
8.15%
|
[11] |
8.15%
|
[7] |
8.15%
|
[11] |
|
|
|
Investment, Interest Rate, Paid in Kind |
|
1.25%
|
[7] |
1.25%
|
[11] |
1.25%
|
[7] |
1.25%
|
[11] |
|
|
|
Interest Rate and Floor |
[11] |
|
|
3.25%
|
|
|
|
3.25%
|
|
|
|
|
Principal Amount |
|
$ 84,314,000
|
[9],[12],[17],[18],[19] |
$ 88,542,000
|
[20],[21] |
|
|
|
|
|
|
|
Investment cost |
|
84,877,000
|
[1],[9],[12],[17],[18],[19] |
88,286,000
|
[4],[20],[21] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 87,283,000
|
[9],[12],[17],[18],[19] |
90,505,000
|
[20],[21] |
|
|
|
|
|
|
|
Communications & Networking | Senior Secured | Exit Fee | Aryaka Networks, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Interest Rate |
[7] |
3.55%
|
|
|
|
3.55%
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
3.55%
|
|
|
|
3.55%
|
|
|
|
|
|
|
Communications & Networking | Senior Secured | Exit Fee | Rocket Lab Global Services, LLC | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Interest Rate |
[7] |
3.20%
|
|
|
|
3.20%
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
3.20%
|
|
|
|
3.20%
|
|
|
|
|
|
|
Communications & Networking | Debt Investments |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 98,596,000
|
[1] |
97,088,000
|
[4] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
100,954,000
|
|
99,230,000
|
|
|
|
|
|
|
|
|
Consumer & Business Products |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
25,497,000
|
|
28,099,000
|
|
|
|
|
|
|
|
|
Consumer & Business Products | Equity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
561,000
|
[1] |
128,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
185,000
|
|
447,000
|
|
|
|
|
|
|
|
|
Consumer & Business Products | Warrant Investment |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
1,712,000
|
[1] |
2,145,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
1,122,000
|
|
4,354,000
|
|
|
|
|
|
|
|
|
Consumer & Business Products | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Principal Amount |
[4] |
|
|
23,162,000
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
23,774,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
24,190,000
|
|
23,298,000
|
|
|
|
|
|
|
|
|
Consumer & Business Products | Grove Collaborative, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[5],[22] |
433,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[5],[22] |
$ 127,000
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
Apr. 30, 2021
|
|
|
|
|
|
|
|
|
|
|
Shares | shares |
[5],[22] |
61,300
|
|
|
|
61,300
|
|
|
|
|
|
|
Consumer & Business Products | Grove Collaborative, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
|
|
433,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
|
|
$ 326,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[6] |
|
|
Apr. 30, 2021
|
|
|
|
|
|
|
|
|
Shares | shares |
|
|
|
83,625
|
|
|
|
83,625
|
|
|
|
|
Consumer & Business Products | Penumbra Brands, LLC (p.k.a. Gadget Guard) | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
|
|
$ 228,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
|
|
$ 0
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[6] |
|
|
Jun. 03, 2014
|
|
|
|
|
|
|
|
|
Shares | shares |
|
|
|
1,662,441
|
|
|
|
1,662,441
|
|
|
|
|
Consumer & Business Products | TechStyle, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 128,000
|
[1] |
$ 128,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 58,000
|
|
$ 447,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Apr. 30, 2010
|
[5] |
Apr. 30, 2010
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
42,989
|
|
42,989
|
|
42,989
|
|
42,989
|
|
|
|
|
Consumer & Business Products | TechStyle, Inc. | Warrant Investment | Preferred Series B |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
$ 1,101,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 365,000
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
Jul. 16, 2013
|
|
|
|
|
|
|
|
|
|
|
Shares | shares |
|
206,185
|
|
|
|
206,185
|
|
|
|
|
|
|
Consumer & Business Products | Gadget Guard, LLC | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
$ 228,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 0
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
Jun. 03, 2014
|
|
|
|
|
|
|
|
|
|
|
Shares | shares |
|
1,662,441
|
|
|
|
1,662,441
|
|
|
|
|
|
|
Consumer & Business Products | The Neat Company | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 365,000
|
[1] |
$ 365,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 0
|
|
$ 0
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Aug. 13, 2014
|
[5] |
Aug. 13, 2014
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
54,054
|
|
54,054
|
|
54,054
|
|
54,054
|
|
|
|
|
Consumer & Business Products | Whoop, Inc. | Warrant Investment | Preferred Series C |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 18,000
|
[1] |
$ 18,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 757,000
|
|
$ 1,847,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Jun. 27, 2018
|
[5] |
Jun. 27, 2018
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
686,270
|
|
686,270
|
|
686,270
|
|
686,270
|
|
|
|
|
Consumer & Business Products | TechStyle, Inc. (p.k.a. Just Fabulous, Inc.) | Warrant Investment | Preferred Series B |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
|
|
$ 1,101,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
|
|
$ 2,181,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[6] |
|
|
Jul. 16, 2013
|
|
|
|
|
|
|
|
|
Shares | shares |
|
|
|
206,185
|
|
|
|
206,185
|
|
|
|
|
Consumer & Business Products | Senior Secured | Grove Collaborative, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-04
|
|
2025-04
|
|
2025-04
|
|
2025-04
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
6.75%
|
|
|
|
6.75%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
5.50%
|
[7] |
5.50%
|
[11] |
5.50%
|
[7] |
5.50%
|
[11] |
|
|
|
Investment, Interest Rate, Floor |
|
8.75%
|
[7] |
8.75%
|
[11] |
8.75%
|
[7] |
8.75%
|
[11] |
|
|
|
Interest Rate and Floor |
[11] |
|
|
6.75%
|
|
|
|
6.75%
|
|
|
|
|
Principal Amount |
|
$ 23,520,000
|
[8] |
$ 23,520,000
|
[23] |
|
|
|
|
|
|
|
Investment cost |
|
23,774,000
|
[1],[8] |
23,162,000
|
[4],[23] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 24,190,000
|
[8] |
23,298,000
|
[23] |
|
|
|
|
|
|
|
Consumer & Business Products | Senior Secured | Exit Fee | Grove Collaborative, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Interest Rate |
[7] |
8.75%
|
|
|
|
8.75%
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
8.75%
|
|
|
|
8.75%
|
|
|
|
|
|
|
Consumer & Business Products | Debt Investments |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Principal Amount |
[4] |
|
|
23,162,000
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
$ 23,774,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
24,190,000
|
|
23,298,000
|
|
|
|
|
|
|
|
|
Diversified Financial Services |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
72,061,000
|
|
65,073,000
|
|
|
|
|
|
|
|
|
Diversified Financial Services | Equity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
28,444,000
|
[1] |
28,041,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
38,022,000
|
|
32,608,000
|
|
|
|
|
|
|
|
|
Diversified Financial Services | Debt Investments Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[4] |
|
|
403,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
|
|
403,000
|
|
|
|
|
|
|
|
|
Diversified Financial Services | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
36,545,000
|
[1] |
33,335,000
|
[4] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
34,039,000
|
|
32,062,000
|
|
|
|
|
|
|
|
|
Diversified Financial Services | Gibraltar Business Capital, LLC | Equity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
28,006,000
|
[1] |
28,006,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 15,623,000
|
|
$ 20,618,000
|
|
|
|
|
|
|
|
|
Shares | shares |
|
11,432,752
|
|
11,432,752
|
|
11,432,752
|
|
11,432,752
|
|
|
|
|
Diversified Financial Services | Gibraltar Business Capital, LLC | Equity | Preferred Series A |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 26,122,000
|
[1],[24] |
$ 26,122,000
|
[2],[25] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 14,489,000
|
[24] |
$ 19,393,000
|
[25] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Mar. 01, 2018
|
[5] |
Mar. 01, 2018
|
[6],[25] |
|
|
|
|
|
|
|
Shares | shares |
|
10,602,752
|
[24] |
10,602,752
|
[25] |
10,602,752
|
[24] |
10,602,752
|
[25] |
|
|
|
Diversified Financial Services | Gibraltar Business Capital, LLC | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,884,000
|
[1],[24] |
$ 1,884,000
|
[2],[25] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 1,134,000
|
[24] |
$ 1,225,000
|
[25] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Mar. 01, 2018
|
[5] |
Mar. 01, 2018
|
[6],[25] |
|
|
|
|
|
|
|
Shares | shares |
|
830,000
|
[24] |
830,000
|
[25] |
830,000
|
[24] |
830,000
|
[25] |
|
|
|
Diversified Financial Services | Gibraltar Business Capital, LLC | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Principal Amount |
|
$ 25,000,000
|
|
$ 25,000,000
|
|
|
|
|
|
|
|
|
Investment cost |
|
24,545,000
|
[1] |
24,485,000
|
[4] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
22,039,000
|
|
23,212,000
|
|
|
|
|
|
|
|
|
Diversified Financial Services | Hercules Adviser LLC | Equity | Member Units |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
35,000
|
[1],[24] |
35,000
|
[2],[25] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 21,945,000
|
[24] |
$ 11,990,000
|
[25] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Mar. 26, 2021
|
[5] |
Mar. 26, 2021
|
[6],[25] |
|
|
|
|
|
|
|
Shares | shares |
|
1
|
[24] |
1
|
[25] |
1
|
[24] |
1
|
[25] |
|
|
|
Diversified Financial Services | Newfront Insurance Holdings, Inc. | Equity | Preferred Series D-2 |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
$ 403,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 454,000
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
Sep. 30, 2021
|
|
|
|
|
|
|
|
|
|
|
Shares | shares |
|
210,282
|
|
|
|
210,282
|
|
|
|
|
|
|
Diversified Financial Services | Debt Investments |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 36,545,000
|
[1] |
$ 33,738,000
|
[4] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 34,039,000
|
|
$ 32,465,000
|
|
|
|
|
|
|
|
|
Diversified Financial Services | Unsecured | Gibraltar Business Capital, LLC | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
2026-09
|
|
|
|
2026-09
|
|
|
|
|
Principal Amount |
[25] |
|
|
$ 15,000,000
|
|
|
|
|
|
|
|
|
Diversified Financial Services | Unsecured | Hercules Adviser LLC | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-06
|
|
|
|
2025-06
|
|
|
|
|
|
|
Investment, Interest Rate, Paid in Cash |
[7] |
5.00%
|
|
|
|
5.00%
|
|
|
|
|
|
|
Principal Amount |
[24] |
$ 12,000,000
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[24] |
12,000,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[24] |
$ 12,000,000
|
|
|
|
|
|
|
|
|
|
|
Diversified Financial Services | Unsecured 14.50% | Gibraltar Business Capital, LLC | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-09
|
|
|
|
2026-09
|
|
|
|
|
|
|
Investment, Interest Rate, Paid in Cash |
|
14.50%
|
[7] |
14.50%
|
[11],[25] |
14.50%
|
[7] |
14.50%
|
[11],[25] |
|
|
|
Principal Amount |
[24] |
$ 15,000,000
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
14,701,000
|
[1],[24] |
$ 14,662,000
|
[4],[25] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 13,033,000
|
[24] |
$ 13,818,000
|
[25] |
|
|
|
|
|
|
|
Diversified Financial Services | Unsecured 11.50% | Gibraltar Business Capital, LLC | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-09
|
|
2026-09
|
|
2026-09
|
|
2026-09
|
|
|
|
|
Investment, Interest Rate, Paid in Cash |
|
11.50%
|
[7] |
11.50%
|
[11],[25] |
11.50%
|
[7] |
11.50%
|
[11],[25] |
|
|
|
Principal Amount |
|
$ 10,000,000
|
[24] |
$ 10,000,000
|
[25] |
|
|
|
|
|
|
|
Investment cost |
|
9,844,000
|
[1],[24] |
9,823,000
|
[4],[25] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
9,006,000
|
[24] |
$ 9,394,000
|
[25] |
|
|
|
|
|
|
|
Diversified Financial Services | Unsecured 5.00 % | Hercules Adviser LLC | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
2023-05
|
|
|
|
2023-05
|
|
|
|
|
Investment, Interest Rate, Paid in Cash |
[11],[25] |
|
|
5.00%
|
|
|
|
5.00%
|
|
|
|
|
Principal Amount |
[25] |
|
|
$ 8,850,000
|
|
|
|
|
|
|
|
|
Investment cost |
[4],[25] |
|
|
8,850,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[25] |
|
|
$ 8,850,000
|
|
|
|
|
|
|
|
|
Diversified Financial Services | Convertible Debt | Newfront Insurance Holdings, Inc. | Debt Investments Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
2022-08
|
|
|
|
2022-08
|
|
|
|
|
Investment, Interest Rate, Floor |
[11],[26] |
|
|
0.19%
|
|
|
|
0.19%
|
|
|
|
|
Investment, Interest Rate, Paid in Kind |
[11],[26] |
|
|
0.19%
|
|
|
|
0.19%
|
|
|
|
|
Principal Amount |
[26] |
|
|
$ 403,000
|
|
|
|
|
|
|
|
|
Investment cost |
[4],[26] |
|
|
403,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[26] |
|
|
403,000
|
|
|
|
|
|
|
|
|
Investment Funds And Vehicles |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
|
|
2,032,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
|
|
1,814,000
|
|
|
|
|
|
|
|
|
Investment Funds And Vehicles | Forbion Growth Opportunities Fund I C V |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[15],[27],[28] |
|
|
2,032,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[15],[27],[28] |
|
|
$ 1,814,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[6],[27],[28] |
|
|
Nov. 16, 2020
|
|
|
|
|
|
|
|
|
Surgical Devices |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
1,536,000
|
|
$ 1,029,000
|
|
|
|
|
|
|
|
|
Surgical Devices | Equity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
1,941,000
|
[1] |
1,941,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
0
|
|
543,000
|
|
|
|
|
|
|
|
|
Surgical Devices | Warrant Investment |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
152,000
|
[1] |
206,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
1,536,000
|
|
486,000
|
|
|
|
|
|
|
|
|
Surgical Devices | Gynesonics, Inc. | Equity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
1,941,000
|
[1] |
1,941,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 0
|
|
$ 543,000
|
|
|
|
|
|
|
|
|
Shares | shares |
|
9,595,178
|
|
9,595,178
|
|
9,595,178
|
|
9,595,178
|
|
|
|
|
Surgical Devices | Gynesonics, Inc. | Equity | Preferred Series D |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 712,000
|
[1] |
$ 712,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 0
|
|
$ 81,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Feb. 08, 2013
|
[5] |
Feb. 08, 2013
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
1,991,157
|
|
1,991,157
|
|
1,991,157
|
|
1,991,157
|
|
|
|
|
Surgical Devices | Gynesonics, Inc. | Equity | Preferred Series B |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 250,000
|
[1] |
$ 250,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 0
|
|
$ 9,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Jan. 18, 2007
|
[5] |
Jan. 18, 2007
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
219,298
|
|
219,298
|
|
219,298
|
|
219,298
|
|
|
|
|
Surgical Devices | Gynesonics, Inc. | Equity | Preferred Series C |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 282,000
|
[1] |
$ 282,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 0
|
|
$ 26,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Jun. 16, 2010
|
[5] |
Jun. 16, 2010
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
656,538
|
|
656,538
|
|
656,538
|
|
656,538
|
|
|
|
|
Surgical Devices | Gynesonics, Inc. | Equity | Preferred Series E |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 429,000
|
[1] |
$ 429,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 0
|
|
$ 131,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Jul. 14, 2015
|
[5] |
Jul. 14, 2015
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
2,786,367
|
|
2,786,367
|
|
2,786,367
|
|
2,786,367
|
|
|
|
|
Surgical Devices | Gynesonics, Inc. | Equity | Preferred Series F |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 118,000
|
[1] |
$ 118,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 0
|
|
$ 123,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Dec. 18, 2018
|
[5] |
Dec. 18, 2018
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
1,523,693
|
|
1,523,693
|
|
1,523,693
|
|
1,523,693
|
|
|
|
|
Surgical Devices | Gynesonics, Inc. | Equity | Series F One Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 150,000
|
[1] |
$ 150,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 0
|
|
$ 173,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Dec. 18, 2018
|
[5] |
Dec. 18, 2018
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
2,418,125
|
|
2,418,125
|
|
2,418,125
|
|
2,418,125
|
|
|
|
|
Surgical Devices | Gynesonics, Inc. | Warrant Investment | Preferred Series C |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 13,000
|
[1] |
$ 67,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 0
|
|
$ 6,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Dec. 05, 2012
|
[5] |
Feb. 08, 2012
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
33,670
|
|
151,123
|
|
33,670
|
|
151,123
|
|
|
|
|
Surgical Devices | TransMedics Group, Inc. (p.k.a Transmedics, Inc.) | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 139,000
|
[1],[5] |
$ 139,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 1,536,000
|
[5] |
$ 480,000
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Nov. 07, 2012
|
[5] |
Nov. 07, 2012
|
|
|
|
|
|
|
|
|
Shares | shares |
|
64,440
|
[5] |
64,440
|
[6] |
64,440
|
[5] |
64,440
|
[6] |
|
|
|
Drug Discovery & Development |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 1,091,827,000
|
|
$ 967,383,000
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Equity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
42,548,000
|
[1] |
33,401,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
32,844,000
|
|
24,860,000
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Warrant Investment |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
7,709,000
|
[1] |
7,393,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
4,074,000
|
|
4,745,000
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Investment Funds & Vehicles [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
2,758,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
2,665,000
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Debt Investments Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
16,378,000
|
[1] |
20,036,000
|
[4] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
16,093,000
|
|
20,036,000
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
1,039,957,000
|
[1] |
916,421,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
1,036,151,000
|
|
915,928,000
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Chemocentryx, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
1,000,000
|
[1],[5],[29] |
1,000,000
|
[2],[6],[27] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 891,000
|
[5],[29] |
$ 628,000
|
[6],[27] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Jun. 15, 2020
|
[5] |
Jun. 15, 2020
|
[6],[27] |
|
|
|
|
|
|
|
Shares | shares |
|
17,241
|
[5],[29] |
17,241
|
[6],[27] |
17,241
|
[5],[29] |
17,241
|
[6],[27] |
|
|
|
Drug Discovery & Development | Akero Therapeutics, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
$ 1,000,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[5],[29] |
$ 1,310,000
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
Sep. 19, 2022
|
|
|
|
|
|
|
|
|
|
|
Shares | shares |
[5],[29] |
38,461
|
|
|
|
38,461
|
|
|
|
|
|
|
Drug Discovery & Development | Akero Therapeutics, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[5],[29] |
$ 56,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[5],[29] |
$ 398,000
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
Jun. 15, 2022
|
|
|
|
|
|
|
|
|
|
|
Shares | shares |
[5],[29] |
18,360
|
|
|
|
18,360
|
|
|
|
|
|
|
Drug Discovery & Development | Albireo Pharma, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,000,000
|
[1],[5],[29] |
$ 1,000,000
|
[2],[6],[27] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 484,000
|
[5],[29] |
$ 582,000
|
[6],[27] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Sep. 14, 2020
|
[5] |
Sep. 14, 2020
|
[6],[27] |
|
|
|
|
|
|
|
Shares | shares |
|
25,000
|
[5],[29] |
25,000
|
[6],[27] |
25,000
|
[5],[29] |
25,000
|
[6],[27] |
|
|
|
Drug Discovery & Development | Albireo Pharma, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 61,000
|
[1],[5],[29] |
$ 61,000
|
[2],[6],[27] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 26,000
|
[5],[29] |
$ 42,000
|
[6],[27] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Jun. 08, 2020
|
[5] |
Jun. 08, 2020
|
[6],[27] |
|
|
|
|
|
|
|
Shares | shares |
|
5,311
|
[5],[29] |
5,311
|
[6],[27] |
5,311
|
[5],[29] |
5,311
|
[6],[27] |
|
|
|
Drug Discovery & Development | Aveo Pharmaceuticals, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,715,000
|
[1],[5] |
$ 1,715,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 1,565,000
|
[5] |
$ 892,000
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Jul. 31, 2011
|
[5] |
Jul. 31, 2011
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
190,179
|
[5] |
190,179
|
[6] |
190,179
|
[5] |
190,179
|
[6] |
|
|
|
Drug Discovery & Development | Axsome Therapeutics, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[5],[19],[22],[29] |
$ 4,165,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[5],[19],[22],[29] |
$ 5,360,000
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
May 09, 2022
|
|
|
|
|
|
|
|
|
|
|
Shares | shares |
[5],[19],[22],[29] |
127,021
|
|
|
|
127,021
|
|
|
|
|
|
|
Drug Discovery & Development | Axsome Therapeutics, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 880,000
|
[1],[5],[19],[29] |
$ 681,000
|
[2],[6],[27] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 783,000
|
[5],[19],[29] |
$ 142,000
|
[6],[27] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Sep. 25, 2020
|
[5] |
Sep. 25, 2020
|
[6],[27] |
|
|
|
|
|
|
|
Shares | shares |
|
40,396
|
[5],[19],[22],[29] |
15,541
|
[6],[27] |
40,396
|
[5],[19],[22],[29] |
15,541
|
[6],[27] |
|
|
|
Drug Discovery & Development | Bicycle Therapeutics PLC | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,871,000
|
[1],[5],[29],[30] |
$ 1,871,000
|
[2],[6],[27],[28] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 2,282,000
|
[5],[29],[30] |
$ 5,971,000
|
[6],[27],[28] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Oct. 05, 2020
|
[5] |
Oct. 05, 2020
|
[6],[27],[28] |
|
|
|
|
|
|
|
Shares | shares |
|
98,100
|
[5],[29],[30] |
98,100
|
[6],[27],[28] |
98,100
|
[5],[29],[30] |
98,100
|
[6],[27],[28] |
|
|
|
Drug Discovery & Development | BridgeBio Pharma, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 2,255,000
|
[1],[5] |
$ 2,255,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 2,299,000
|
[5] |
$ 3,859,000
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Jun. 21, 2018
|
[5] |
Jun. 21, 2018
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
231,329
|
[5] |
231,329
|
[6] |
231,329
|
[5] |
231,329
|
[6] |
|
|
|
Drug Discovery & Development | Cellarity, Inc. | Warrant Investment | Preferred Series B |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 287,000
|
[1],[31] |
$ 287,000
|
[2],[32] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 370,000
|
[31] |
$ 287,000
|
[32] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Dec. 08, 2021
|
[5] |
Dec. 08, 2021
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
100,000
|
[31] |
100,000
|
[32] |
100,000
|
[31] |
100,000
|
[32] |
|
|
|
Drug Discovery & Development | Century Therapeutics, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 37,000
|
[1],[5] |
$ 37,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 16,000
|
[5] |
$ 64,000
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Sep. 14, 2020
|
[5] |
Sep. 14, 2020
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
16,112
|
[5] |
16,112
|
[6] |
16,112
|
[5] |
16,112
|
[6] |
|
|
|
Drug Discovery & Development | enGene, Inc. | Warrant Investment | Preferred Series 3 |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[29],[30] |
$ 72,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[29],[30] |
$ 31,000
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
Dec. 30, 2021
|
|
|
|
|
|
|
|
|
|
|
Shares | shares |
[29],[30] |
133,692
|
|
|
|
133,692
|
|
|
|
|
|
|
Drug Discovery & Development | enGene, Inc. | Warrant Investment | Preferred Series 3 Class C |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[27],[28] |
|
|
$ 64,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[27],[28] |
|
|
$ 64,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[6],[27],[28] |
|
|
Dec. 30, 2021
|
|
|
|
|
|
|
|
|
Shares | shares |
[27],[28] |
|
|
84,714
|
|
|
|
84,714
|
|
|
|
|
Drug Discovery & Development | Hibercell, Inc. | Equity | Preferred Series B |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 4,250,000
|
[1],[31] |
$ 4,250,000
|
[2],[32] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 2,917,000
|
[31] |
$ 3,264,000
|
[32] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
May 07, 2021
|
[5] |
May 07, 2021
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
3,466,840
|
[31] |
3,466,840
|
[32] |
3,466,840
|
[31] |
3,466,840
|
[32] |
|
|
|
Drug Discovery & Development | HilleVax, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[5] |
$ 4,000,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[5] |
$ 4,021,000
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
May 03, 2022
|
|
|
|
|
|
|
|
|
|
|
Shares | shares |
[5] |
235,295
|
|
|
|
235,295
|
|
|
|
|
|
|
Drug Discovery & Development | Humanigen, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 800,000
|
[1],[5],[29] |
$ 800,000
|
[2],[6],[27] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 8,000
|
[5],[29] |
$ 161,000
|
[6],[27] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Mar. 31, 2021
|
[5] |
Mar. 31, 2021
|
[6],[27] |
|
|
|
|
|
|
|
Shares | shares |
|
43,243
|
[5],[29] |
43,243
|
[6],[27] |
43,243
|
[5],[29] |
43,243
|
[6],[27] |
|
|
|
Drug Discovery & Development | Kaleido Biosciences, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[6] |
|
|
$ 1,000,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[6] |
|
|
$ 207,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[6] |
|
|
Feb. 10, 2021
|
|
|
|
|
|
|
|
|
Shares | shares |
[6] |
|
|
86,585
|
|
|
|
86,585
|
|
|
|
|
Drug Discovery & Development | Madrigal Pharmaceutical, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[5],[29] |
$ 177,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[5],[29] |
$ 214,000
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
May 09, 2022
|
|
|
|
|
|
|
|
|
|
|
Shares | shares |
[5],[29] |
10,131
|
|
|
|
10,131
|
|
|
|
|
|
|
Drug Discovery & Development | Phathom Pharmaceuticals, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 848,000
|
[1],[5],[19],[29],[31] |
$ 848,000
|
[2],[6],[27],[32] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 113,000
|
[5],[19],[29],[31] |
$ 307,000
|
[6],[21],[27],[32] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Sep. 17, 2021
|
[5] |
Sep. 17, 2021
|
[6],[27] |
|
|
|
|
|
|
|
Shares | shares |
|
64,687
|
[5],[19],[29],[31] |
64,687
|
[6],[21],[27],[32] |
64,687
|
[5],[19],[29],[31] |
64,687
|
[6],[21],[27],[32] |
|
|
|
Drug Discovery & Development | Provention Bio, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[5] |
$ 281,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[5] |
$ 224,000
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
Sep. 15, 2022
|
|
|
|
|
|
|
|
|
|
|
Shares | shares |
[5] |
111,934
|
|
|
|
111,934
|
|
|
|
|
|
|
Drug Discovery & Development | Redshift Bioanalytics, Inc. | Warrant Investment |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[31] |
$ 18,000
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Redshift Bioanalytics, Inc. | Warrant Investment | Preferred Series E |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[31] |
$ 20,000
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
Mar. 23, 2022
|
|
|
|
|
|
|
|
|
|
|
Shares | shares |
[31] |
475,510
|
|
|
|
475,510
|
|
|
|
|
|
|
Drug Discovery & Development | Scynexis, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 296,000
|
[1],[5] |
$ 188,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 47,000
|
[5] |
$ 142,000
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
May 14, 2021
|
[5] |
May 14, 2021
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
106,035
|
[5] |
90,887
|
[6] |
106,035
|
[5] |
90,887
|
[6] |
|
|
|
Drug Discovery & Development | Tarsus Pharmaceuticals, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[5],[29] |
$ 2,100,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[5],[29] |
$ 2,663,000
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
May 05, 2022
|
|
|
|
|
|
|
|
|
|
|
Shares | shares |
[5],[29] |
155,555
|
|
|
|
155,555
|
|
|
|
|
|
|
Drug Discovery & Development | TG Therapeutics, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,033,000
|
[1],[5],[18],[29] |
$ 1,033,000
|
[2],[6],[27],[33] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 335,000
|
[5],[18],[29] |
$ 2,172,000
|
[6],[27],[33] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Feb. 28, 2019
|
[5] |
Feb. 28, 2019
|
[6],[27] |
|
|
|
|
|
|
|
Shares | shares |
|
231,613
|
[5],[18],[29] |
231,613
|
[6],[27],[33] |
231,613
|
[5],[18],[29] |
231,613
|
[6],[27],[33] |
|
|
|
Drug Discovery & Development | Uni Qure B V | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 332,000
|
[1],[5],[19],[29],[30] |
$ 332,000
|
[2],[6],[21],[27],[28] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 322,000
|
[5],[19],[29],[30] |
$ 356,000
|
[6],[21],[27],[28] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Jan. 31, 2019
|
[5] |
Jan. 31, 2019
|
[6],[27],[28] |
|
|
|
|
|
|
|
Shares | shares |
|
17,175
|
[5],[19],[29],[30] |
17,175
|
[6],[21],[27],[28] |
17,175
|
[5],[19],[29],[30] |
17,175
|
[6],[21],[27],[28] |
|
|
|
Drug Discovery & Development | Valo Health L L C | Equity | Preferred Series B |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 3,000,000
|
[1] |
$ 3,000,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 3,622,000
|
|
$ 4,650,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Dec. 11, 2020
|
[5] |
Dec. 11, 2020
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
510,308
|
|
510,308
|
|
510,308
|
|
510,308
|
|
|
|
|
Drug Discovery & Development | Valo Health L L C | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 242,000
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
Jun. 15, 2020
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Valo Health L L C | Warrant Investment | Common Units |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
$ 256,000
|
|
|
|
|
|
|
|
|
|
|
Shares | shares |
|
102,216
|
|
|
|
102,216
|
|
|
|
|
|
|
Drug Discovery & Development | X Four Pharmaceuticals Inc | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 2,522,000
|
[1],[5] |
$ 1,641,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 1,901,000
|
[5] |
$ 454,000
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Nov. 26, 2019
|
[5] |
Nov. 26, 2019
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
1,111,519
|
[5] |
198,277
|
[6] |
1,111,519
|
[5] |
198,277
|
[6] |
|
|
|
Drug Discovery & Development | X Four Pharmaceuticals Inc | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 792,000
|
[1],[5] |
$ 673,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 628,000
|
[5] |
$ 2,000
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Mar. 18, 2019
|
[5] |
Mar. 18, 2019
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
1,021,576
|
[5] |
108,334
|
[6] |
1,021,576
|
[5] |
108,334
|
[6] |
|
|
|
Drug Discovery & Development | Applied Molecular Transport | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 42,000
|
[1],[5],[29] |
$ 42,000
|
[2],[6],[27] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 1,000
|
[5],[29] |
$ 14,000
|
[6],[27] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Apr. 06, 2021
|
[5] |
Apr. 06, 2021
|
[6],[27] |
|
|
|
|
|
|
|
Shares | shares |
|
1,000
|
[5],[29] |
1,000
|
[6],[27] |
1,000
|
[5],[29] |
1,000
|
[6],[27] |
|
|
|
Drug Discovery & Development | Avalo Therapeutics, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,000,000
|
[1],[5] |
$ 1,000,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 33,000
|
[5] |
$ 202,000
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Aug. 19, 2014
|
[5] |
Aug. 19, 2014
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
9,924
|
[5] |
119,087
|
[6] |
9,924
|
[5] |
119,087
|
[6] |
|
|
|
Drug Discovery & Development | Concert Pharmaceuticals, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,367,000
|
[1],[5],[29] |
$ 1,367,000
|
[2],[6],[27] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 474,000
|
[5],[29] |
$ 223,000
|
[6],[27] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Feb. 13, 2019
|
[5] |
Feb. 13, 2019
|
[6],[27] |
|
|
|
|
|
|
|
Shares | shares |
|
70,796
|
[5],[29] |
70,796
|
[6],[27] |
70,796
|
[5],[29] |
70,796
|
[6],[27] |
|
|
|
Drug Discovery & Development | Concert Pharmaceuticals, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[6],[27] |
|
|
$ 178,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[6],[27] |
|
|
$ 3,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[6],[27] |
|
|
Jun. 08, 2017
|
|
|
|
|
|
|
|
|
Shares | shares |
[6],[27] |
|
|
61,273
|
|
|
|
61,273
|
|
|
|
|
Drug Discovery & Development | Dare Biosciences, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,000,000
|
[1],[5] |
$ 1,000,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 14,000
|
[5] |
$ 27,000
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Jan. 08, 2015
|
[5] |
Jan. 08, 2015
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
13,550
|
[5] |
13,550
|
[6] |
13,550
|
[5] |
13,550
|
[6] |
|
|
|
Drug Discovery & Development | Dynavax Technologies | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 550,000
|
[1],[5],[29] |
$ 550,000
|
[2],[6],[27] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 209,000
|
[5],[29] |
$ 281,000
|
[6],[27] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Jul. 22, 2015
|
[5] |
Jul. 22, 2015
|
[6],[27] |
|
|
|
|
|
|
|
Shares | shares |
|
20,000
|
[5],[29] |
20,000
|
[6],[27] |
20,000
|
[5],[29] |
20,000
|
[6],[27] |
|
|
|
Drug Discovery & Development | NorthSea Therapeutics | Equity | Preferred Series C |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 2,000,000
|
[1],[29],[30] |
$ 2,000,000
|
[2],[27],[28] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 1,515,000
|
[29],[30] |
$ 2,000,000
|
[27],[28] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Dec. 15, 2021
|
[5] |
Dec. 15, 2021
|
[6],[27],[28] |
|
|
|
|
|
|
|
Shares | shares |
|
983
|
[29],[30] |
983
|
[27],[28] |
983
|
[29],[30] |
983
|
[27],[28] |
|
|
|
Drug Discovery & Development | Paratek Pharmaceuticals, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 2,744,000
|
[1],[5] |
$ 2,744,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 196,000
|
[5] |
$ 343,000
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Feb. 26, 2007
|
[5] |
Feb. 26, 2007
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
76,362
|
[5] |
76,362
|
[6] |
76,362
|
[5] |
76,362
|
[6] |
|
|
|
Drug Discovery & Development | Paratek Pharmaceuticals, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 520,000
|
[1],[5] |
$ 546,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 72,000
|
[5] |
$ 427,000
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Aug. 01, 2018
|
[5] |
Jun. 27, 2017
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
426,866
|
[5] |
432,240
|
[6] |
426,866
|
[5] |
432,240
|
[6] |
|
|
|
Drug Discovery & Development | Rocket Pharmaceuticals, Ltd. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,500,000
|
[1],[5] |
$ 1,500,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 15,000
|
[5] |
$ 21,000
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Aug. 22, 2007
|
[5] |
Aug. 22, 2007
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
944
|
[5] |
944
|
[6] |
944
|
[5] |
944
|
[6] |
|
|
|
Drug Discovery & Development | Savara, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 203,000
|
[1],[5] |
$ 202,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 17,000
|
[5] |
$ 14,000
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Aug. 11, 2015
|
[5] |
Aug. 11, 2015
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
11,119
|
[5] |
11,119
|
[6] |
11,119
|
[5] |
11,119
|
[6] |
|
|
|
Drug Discovery & Development | Sio Gene Therapies, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 1,269,000
|
[1],[5] |
$ 1,269,000
|
[2],[6],[27] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 4,000
|
[5] |
$ 21,000
|
[6],[27] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Feb. 02, 2017
|
[5] |
Feb. 02, 2017
|
[6],[27] |
|
|
|
|
|
|
|
Shares | shares |
|
16,228
|
[5] |
16,228
|
[6],[27] |
16,228
|
[5] |
16,228
|
[6],[27] |
|
|
|
Drug Discovery & Development | Tricida, Inc. | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 863,000
|
[1],[5] |
$ 863,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 721,000
|
[5] |
$ 658,000
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Feb. 28, 2018
|
[5] |
Feb. 28, 2018
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
68,816
|
[5] |
68,816
|
[6] |
68,816
|
[5] |
68,816
|
[6] |
|
|
|
Drug Discovery & Development | Tricida, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 280,000
|
[1],[5] |
$ 280,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 22,000
|
[5] |
$ 20,000
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Mar. 27, 2019
|
[5] |
Mar. 27, 2019
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
31,352
|
[5] |
31,352
|
[6] |
31,352
|
[5] |
31,352
|
[6] |
|
|
|
Drug Discovery & Development | ADMA Biologics, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 295,000
|
[1],[5] |
$ 295,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 2,000
|
[5] |
$ 1,000
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Dec. 21, 2012
|
[5] |
Dec. 21, 2012
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
89,750
|
[5] |
89,750
|
[6] |
89,750
|
[5] |
89,750
|
[6] |
|
|
|
Drug Discovery & Development | Brickell Biotech, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[6] |
|
|
$ 119,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[6] |
|
|
$ 0
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[6] |
|
|
Feb. 18, 2016
|
|
|
|
|
|
|
|
|
Shares | shares |
[6] |
|
|
9,005
|
|
|
|
9,005
|
|
|
|
|
Drug Discovery & Development | Dermavant Sciences Ltd. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 101,000
|
[1],[18],[29],[30] |
$ 101,000
|
[2],[27],[33] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 104,000
|
[18],[29],[30] |
$ 354,000
|
[27],[33] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
May 31, 2019
|
[5] |
May 31, 2019
|
[6],[27] |
|
|
|
|
|
|
|
Shares | shares |
|
223,642
|
[18],[29],[30] |
223,642
|
[27],[33] |
223,642
|
[18],[29],[30] |
223,642
|
[27],[33] |
|
|
|
Drug Discovery & Development | Evofem Biosciences, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 266,000
|
[1],[5] |
$ 266,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 0
|
[5] |
$ 0
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Jun. 11, 2014
|
[5] |
Jun. 11, 2014
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
520
|
[5] |
7,806
|
[6] |
520
|
[5] |
7,806
|
[6] |
|
|
|
Drug Discovery & Development | Myovant Sciences, Ltd. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 460,000
|
[1],[5],[29],[30] |
$ 460,000
|
[2],[6],[27] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 429,000
|
[5],[29],[30] |
$ 267,000
|
[6],[27] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Oct. 16, 2017
|
[5] |
Oct. 16, 2017
|
[6],[27] |
|
|
|
|
|
|
|
Shares | shares |
|
73,710
|
[5],[29],[30] |
73,710
|
[6],[27] |
73,710
|
[5],[29],[30] |
73,710
|
[6],[27] |
|
|
|
Drug Discovery & Development | Stealth Bio Therapeutics Corp. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 158,000
|
[1],[5],[29],[30] |
$ 158,000
|
[2],[6],[27] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 0
|
[5],[29],[30] |
$ 0
|
[6],[27] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Jun. 30, 2017
|
[5] |
Jun. 30, 2017
|
[6],[27] |
|
|
|
|
|
|
|
Shares | shares |
|
500,000
|
[5],[29],[30] |
500,000
|
[6],[27] |
500,000
|
[5],[29],[30] |
500,000
|
[6],[27] |
|
|
|
Drug Discovery & Development | Yumanity Therapeutics, Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 110,000
|
[1],[5] |
$ 110,000
|
[2],[6] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 0
|
[5] |
$ 3,000
|
[6] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Dec. 20, 2019
|
[5] |
Dec. 20, 2019
|
[6] |
|
|
|
|
|
|
|
Shares | shares |
|
15,414
|
[5] |
15,414
|
[6] |
15,414
|
[5] |
15,414
|
[6] |
|
|
|
Drug Discovery & Development | Fresh Tracks Therapeutics, Inc. (p.k.a. Brickell Biotech, Inc.) | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[5] |
$ 119,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[5] |
$ 0
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
Feb. 18, 2016
|
|
|
|
|
|
|
|
|
|
|
Shares | shares |
[5] |
200
|
|
|
|
200
|
|
|
|
|
|
|
Drug Discovery & Development | Forbion Growth Opportunities Fund I C V | Investment Funds & Vehicles [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[10],[29],[30] |
$ 2,353,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[10],[29],[30] |
$ 2,291,000
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
Nov. 16, 2020
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Forbion Growth Opportunities Fund I I C V | Investment Funds & Vehicles [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[10],[29],[30] |
$ 405,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[10],[29],[30] |
$ 374,000
|
|
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[5] |
Jun. 23, 2022
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Valo Health, LLC (p.k.a. Integral Health Holdings, LLC) | Warrant Investment | Common Units |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
|
|
$ 256,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
|
|
$ 441,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[6] |
|
|
Jun. 15, 2020
|
|
|
|
|
|
|
|
|
Shares | shares |
|
|
|
102,216
|
|
|
|
102,216
|
|
|
|
|
Drug Discovery & Development | Acacia Pharma Inc. | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
|
$ 304,000
|
[1],[29],[30] |
$ 305,000
|
[2],[6],[27],[28] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 0
|
[29],[30] |
$ 6,000
|
[6],[27],[28] |
|
|
|
|
|
|
|
Investment, Acquisition Date |
|
Jun. 29, 2018
|
[5] |
Jun. 29, 2018
|
[6],[27],[28] |
|
|
|
|
|
|
|
Shares | shares |
|
201,330
|
[29],[30] |
201,330
|
[6],[27],[28] |
201,330
|
[29],[30] |
201,330
|
[6],[27],[28] |
|
|
|
Drug Discovery & Development | Genocea Biosciences Inc | Equity | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[6] |
|
|
$ 2,000,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[6] |
|
|
$ 32,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[6] |
|
|
Nov. 20, 2014
|
|
|
|
|
|
|
|
|
Shares | shares |
[6] |
|
|
27,933
|
|
|
|
27,933
|
|
|
|
|
Drug Discovery & Development | Genocea Biosciences Inc | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[6] |
|
|
$ 165,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[6] |
|
|
$ 1,000
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[6] |
|
|
Apr. 24, 2018
|
|
|
|
|
|
|
|
|
Shares | shares |
[6] |
|
|
41,176
|
|
|
|
41,176
|
|
|
|
|
Drug Discovery & Development | Motif Bio P L C | Warrant Investment | Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[27] |
|
|
$ 282,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[27] |
|
|
$ 0
|
|
|
|
|
|
|
|
|
Investment, Acquisition Date |
[6],[27] |
|
|
Jan. 27, 2020
|
|
|
|
|
|
|
|
|
Shares | shares |
[27] |
|
|
121,337,041
|
|
|
|
121,337,041
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Chemocentryx, Inc. | Debt Investments Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2022-12
|
|
2022-12
|
|
2022-12
|
|
2022-12
|
|
|
|
|
Investment Interest Rate |
[11],[27] |
|
|
6.25%
|
|
|
|
6.25%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
3.30%
|
[7] |
3.30%
|
[11],[27] |
3.30%
|
[7] |
3.30%
|
[11],[27] |
|
|
|
Investment, Interest Rate, Floor |
|
8.05%
|
[7] |
8.05%
|
[11],[27] |
8.05%
|
[7] |
8.05%
|
[11],[27] |
|
|
|
Interest Rate and Floor |
[11],[27] |
|
|
6.25%
|
|
|
|
6.25%
|
|
|
|
|
Principal Amount |
|
$ 11,451,000
|
[17],[29] |
$ 18,951,000
|
[27] |
|
|
|
|
|
|
|
Investment cost |
|
12,677,000
|
[1],[17],[29] |
20,036,000
|
[4],[27] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 12,780,000
|
[17],[29] |
$ 20,036,000
|
[27] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Chemocentryx, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-02
|
|
2025-02
|
|
2025-02
|
|
2025-02
|
|
|
|
|
Investment Interest Rate |
[11],[27] |
|
|
7.15%
|
|
|
|
7.15%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
3.25%
|
[7] |
3.25%
|
[11],[27] |
3.25%
|
[7] |
3.25%
|
[11],[27] |
|
|
|
Investment, Interest Rate, Floor |
|
8.50%
|
[7] |
8.50%
|
[11],[27] |
8.50%
|
[7] |
8.50%
|
[11],[27] |
|
|
|
Interest Rate and Floor |
[11],[27] |
|
|
7.15%
|
|
|
|
7.15%
|
|
|
|
|
Principal Amount |
|
$ 5,000,000
|
[17],[29] |
$ 5,000,000
|
[27] |
|
|
|
|
|
|
|
Investment cost |
|
5,214,000
|
[1],[17],[29] |
5,161,000
|
[2],[27] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 5,408,000
|
[17],[29] |
$ 5,070,000
|
[27] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Nabriva Therapeutics | Debt Investments Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2023-06
|
|
|
|
2023-06
|
|
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[7] |
4.30%
|
|
|
|
4.30%
|
|
|
|
|
|
|
Investment, Interest Rate, Floor |
[7] |
9.80%
|
|
|
|
9.80%
|
|
|
|
|
|
|
Principal Amount |
[17],[29],[30] |
$ 3,077,000
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[17],[29],[30] |
3,701,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[17],[29],[30] |
$ 3,313,000
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Nabriva Therapeutics | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
2023-06
|
|
|
|
2023-06
|
|
|
|
|
Investment Interest Rate |
[11],[27],[28] |
|
|
6.95%
|
|
|
|
6.95%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[11],[27],[28] |
|
|
4.30%
|
|
|
|
4.30%
|
|
|
|
|
Investment, Interest Rate, Floor |
[11],[27],[28] |
|
|
9.80%
|
|
|
|
9.80%
|
|
|
|
|
Interest Rate and Floor |
[11],[27],[28] |
|
|
6.95%
|
|
|
|
6.95%
|
|
|
|
|
Principal Amount |
[27],[28] |
|
|
$ 5,000,000
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[27],[28] |
|
|
5,500,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[27],[28] |
|
|
$ 5,459,000
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Akero Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2027-01
|
|
|
|
2027-01
|
|
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[7] |
3.65%
|
|
|
|
3.65%
|
|
|
|
|
|
|
Investment, Interest Rate, Floor |
[7] |
7.65%
|
|
|
|
7.65%
|
|
|
|
|
|
|
Principal Amount |
[10],[29] |
$ 5,000,000
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[10],[29] |
4,966,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[10],[29] |
$ 4,983,000
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Albireo Pharma, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
2024-07
|
|
|
|
2024-07
|
|
|
|
|
Investment Interest Rate |
[11],[27] |
|
|
6.95%
|
|
|
|
6.95%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[11],[27] |
|
|
5.90%
|
|
|
|
5.90%
|
|
|
|
|
Investment, Interest Rate, Floor |
[11],[27] |
|
|
9.15%
|
|
|
|
9.15%
|
|
|
|
|
Interest Rate and Floor |
[11],[27] |
|
|
6.95%
|
|
|
|
6.95%
|
|
|
|
|
Principal Amount |
[14],[27] |
|
|
$ 10,000,000
|
|
|
|
|
|
|
|
|
Investment cost |
[4],[14],[27] |
|
|
10,229,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[14],[27] |
|
|
$ 10,268,000
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Alladapt Immunotherapeutics Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-09
|
|
|
|
2026-09
|
|
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[7] |
3.65%
|
|
|
|
3.65%
|
|
|
|
|
|
|
Investment, Interest Rate, Floor |
[7] |
8.40%
|
|
|
|
8.40%
|
|
|
|
|
|
|
Principal Amount |
[10] |
$ 15,000,000
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[10] |
14,858,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[10] |
$ 14,858,000
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Aldeyra Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2023-10
|
|
2023-10
|
|
2023-10
|
|
2023-10
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
6.95%
|
|
|
|
6.95%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
3.10%
|
[7] |
3.10%
|
[11] |
3.10%
|
[7] |
3.10%
|
[11] |
|
|
|
Investment, Interest Rate, Floor |
|
8.60%
|
[7] |
8.60%
|
[11] |
8.60%
|
[7] |
8.60%
|
[11] |
|
|
|
Interest Rate and Floor |
[11] |
|
|
6.95%
|
|
|
|
6.95%
|
|
|
|
|
Principal Amount |
|
$ 15,000,000
|
[12] |
$ 15,000,000
|
|
|
|
|
|
|
|
|
Investment cost |
|
15,817,000
|
[1],[12] |
15,639,000
|
[4] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 15,608,000
|
[12] |
$ 15,653,000
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Applied Genetic Technologies Corporation | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-04
|
|
2024-04
|
|
2024-04
|
|
2024-04
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
9.75%
|
|
|
|
9.75%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
6.50%
|
[7] |
6.50%
|
[11] |
6.50%
|
[7] |
6.50%
|
[11] |
|
|
|
Investment, Interest Rate, Floor |
[7] |
9.75%
|
|
|
|
9.75%
|
|
|
|
|
|
|
Interest Rate and Floor |
[11] |
|
|
9.75%
|
|
|
|
9.75%
|
|
|
|
|
Principal Amount |
|
$ 15,609,000
|
[17] |
$ 20,000,000
|
|
|
|
|
|
|
|
|
Investment cost |
|
16,450,000
|
[1],[17] |
20,416,000
|
[4] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 16,308,000
|
[17] |
$ 20,339,000
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | ATAI Life Sciences N.V. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-08
|
|
|
|
2026-08
|
|
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[7] |
4.55%
|
|
|
|
4.55%
|
|
|
|
|
|
|
Investment, Interest Rate, Floor |
[7] |
8.55%
|
|
|
|
8.55%
|
|
|
|
|
|
|
Principal Amount |
[10],[29],[30] |
$ 10,500,000
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[10],[29],[30] |
10,467,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[10],[29],[30] |
$ 10,467,000
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Aveo Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-09
|
|
2024-09
|
|
2024-09
|
|
2024-09
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
6.40%
|
[7] |
6.40%
|
[11] |
6.40%
|
[7] |
6.40%
|
[11] |
|
|
|
Investment, Interest Rate, Floor |
|
9.65%
|
[7] |
9.65%
|
[11] |
9.65%
|
[7] |
9.65%
|
[11] |
|
|
|
Principal Amount |
|
$ 40,000,000
|
[12],[31] |
$ 40,000,000
|
[14],[32] |
|
|
|
|
|
|
|
Investment cost |
|
41,439,000
|
[1],[12],[31] |
40,842,000
|
[4],[14],[32] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 41,374,000
|
[12],[31] |
$ 40,776,000
|
[14],[32] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Axsome Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-10
|
|
2026-10
|
|
2026-10
|
|
2026-10
|
|
|
|
|
Investment Interest Rate |
[11],[27] |
|
|
5.82%
|
|
|
|
5.82%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
5.70%
|
[7] |
5.70%
|
[11],[27] |
5.70%
|
[7] |
5.70%
|
[11],[27] |
|
|
|
Investment, Interest Rate, Floor |
|
8.95%
|
[7] |
8.95%
|
[11],[27] |
8.95%
|
[7] |
8.95%
|
[11],[27] |
|
|
|
Interest Rate and Floor |
[11],[27] |
|
|
5.82%
|
|
|
|
5.82%
|
|
|
|
|
Principal Amount |
|
$ 81,725,000
|
[10],[12],[18],[19],[29] |
$ 50,000,000
|
[27],[33] |
|
|
|
|
|
|
|
Investment cost |
|
81,388,000
|
[1],[10],[12],[18],[19],[29] |
49,542,000
|
[4],[27],[33] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 79,295,000
|
[10],[12],[18],[19],[29] |
$ 48,859,000
|
[27],[33] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Bicycle Therapeutics PLC | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-07
|
|
2024-10
|
|
2025-07
|
|
2024-10
|
|
|
|
|
Investment Interest Rate |
[11],[27],[28] |
|
|
5.00%
|
|
|
|
5.00%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
4.55%
|
[7] |
5.60%
|
[11],[27],[28] |
4.55%
|
[7] |
5.60%
|
[11],[27],[28] |
|
|
|
Investment, Interest Rate, Floor |
|
8.05%
|
[7] |
8.85%
|
[11],[27],[28] |
8.05%
|
[7] |
8.85%
|
[11],[27],[28] |
|
|
|
Interest Rate and Floor |
[11],[27],[28] |
|
|
5.00%
|
|
|
|
5.00%
|
|
|
|
|
Principal Amount |
|
$ 11,500,000
|
[12],[18],[29],[30] |
$ 24,000,000
|
[14],[15],[27],[28],[33] |
|
|
|
|
|
|
|
Investment cost |
|
11,724,000
|
[1],[12],[18],[29],[30] |
24,271,000
|
[4],[14],[15],[27],[28],[33] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 11,619,000
|
[12],[18],[29],[30] |
$ 24,454,000
|
[14],[15],[27],[28],[33] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | BiomX, INC | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-09
|
|
2025-09
|
|
2025-09
|
|
2025-09
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
5.70%
|
[7] |
5.70%
|
[11],[27],[28] |
5.70%
|
[7] |
5.70%
|
[11],[27],[28] |
|
|
|
Investment, Interest Rate, Floor |
|
8.95%
|
[7] |
8.95%
|
[11],[27],[28] |
8.95%
|
[7] |
8.95%
|
[11],[27],[28] |
|
|
|
Principal Amount |
|
$ 9,000,000
|
[12],[29],[30] |
$ 9,000,000
|
[14],[27],[28] |
|
|
|
|
|
|
|
Investment cost |
|
9,125,000
|
[1],[12],[29],[30] |
8,980,000
|
[4],[14],[27],[28] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 9,004,000
|
[12],[29],[30] |
$ 8,980,000
|
[14],[27],[28] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | BridgeBio Pharma, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-11
|
|
2026-11
|
|
2026-11
|
|
2026-11
|
|
|
|
|
Investment, Interest Rate, Paid in Cash |
|
9.00%
|
[7] |
9.00%
|
[11] |
9.00%
|
[7] |
9.00%
|
[11] |
|
|
|
Investment Interest Rate |
[11] |
|
|
2.00%
|
|
|
|
2.00%
|
|
|
|
|
Interest Rate and Floor |
[11] |
|
|
2.00%
|
|
|
|
2.00%
|
|
|
|
|
Principal Amount |
|
$ 37,022,000
|
[9],[17],[18] |
$ 38,000,000
|
|
|
|
|
|
|
|
|
Investment cost |
|
36,694,000
|
[1],[9],[17],[18] |
37,462,000
|
[4] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 33,561,000
|
[9],[17],[18] |
$ 37,462,000
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Cellarity, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-06
|
|
2026-06
|
|
2026-06
|
|
2026-06
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
3.75%
|
|
|
|
3.75%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
5.70%
|
[7] |
5.70%
|
[11] |
5.70%
|
[7] |
5.70%
|
[11] |
|
|
|
Investment, Interest Rate, Floor |
|
8.95%
|
[7] |
8.95%
|
[11] |
8.95%
|
[7] |
8.95%
|
[11] |
|
|
|
Interest Rate and Floor |
[11] |
|
|
3.75%
|
|
|
|
3.75%
|
|
|
|
|
Principal Amount |
|
$ 30,000,000
|
[17],[31] |
$ 30,000,000
|
[32] |
|
|
|
|
|
|
|
Investment cost |
|
29,734,000
|
[1],[17],[31] |
29,422,000
|
[4],[32] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 29,943,000
|
[17],[31] |
$ 29,422,000
|
[32] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Century Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-04
|
|
2024-04
|
|
2024-04
|
|
2024-04
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
3.95%
|
|
|
|
3.95%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
6.30%
|
[7] |
6.30%
|
[11] |
6.30%
|
[7] |
6.30%
|
[11] |
|
|
|
Investment, Interest Rate, Floor |
|
9.55%
|
[7] |
9.55%
|
[11] |
9.55%
|
[7] |
9.55%
|
[11] |
|
|
|
Interest Rate and Floor |
[11] |
|
|
3.95%
|
|
|
|
3.95%
|
|
|
|
|
Principal Amount |
|
$ 10,000,000
|
[12] |
$ 10,000,000
|
[14] |
|
|
|
|
|
|
|
Investment cost |
|
10,197,000
|
[1],[12] |
10,075,000
|
[4],[14] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 10,261,000
|
[12] |
$ 10,361,000
|
[14] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Codiak Biosciences, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-10
|
|
2025-10
|
|
2025-10
|
|
2025-10
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
5.50%
|
|
|
|
5.50%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
5.00%
|
[7] |
5.00%
|
[11] |
5.00%
|
[7] |
5.00%
|
[11] |
|
|
|
Investment, Interest Rate, Floor |
|
8.25%
|
[7] |
8.25%
|
[11] |
8.25%
|
[7] |
8.25%
|
[11] |
|
|
|
Interest Rate and Floor |
[11] |
|
|
5.50%
|
|
|
|
5.50%
|
|
|
|
|
Principal Amount |
|
$ 25,000,000
|
[12] |
$ 25,000,000
|
[14] |
|
|
|
|
|
|
|
Investment cost |
|
25,681,000
|
[1],[12] |
25,459,000
|
[2],[14] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 25,076,000
|
[12] |
$ 25,316,000
|
[14] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Corium, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-09
|
|
2026-09
|
|
2026-09
|
|
2026-09
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
7.75%
|
|
|
|
7.75%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
5.70%
|
[7] |
5.70%
|
[11] |
5.70%
|
[7] |
5.70%
|
[11] |
|
|
|
Investment, Interest Rate, Floor |
|
8.95%
|
[7] |
8.95%
|
[11] |
8.95%
|
[7] |
8.95%
|
[11] |
|
|
|
Interest Rate and Floor |
[11] |
|
|
7.75%
|
|
|
|
7.75%
|
|
|
|
|
Principal Amount |
|
$ 132,675,000
|
[17],[19] |
$ 91,500,000
|
[21] |
|
|
|
|
|
|
|
Investment cost |
|
133,069,000
|
[1],[17],[19] |
90,997,000
|
[2],[21] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 135,828,000
|
[17],[19] |
$ 90,997,000
|
[21] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Eloxx Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-04
|
|
2025-04
|
|
2025-04
|
|
2025-04
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
6.25%
|
|
|
|
6.25%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[7] |
6.25%
|
|
|
|
6.25%
|
|
|
|
|
|
|
Investment, Interest Rate, Floor |
|
9.50%
|
[7] |
9.50%
|
[11] |
9.50%
|
[7] |
9.50%
|
[11] |
|
|
|
Interest Rate and Floor |
[11] |
|
|
6.25%
|
|
|
|
6.25%
|
|
|
|
|
Principal Amount |
|
$ 12,500,000
|
[31] |
$ 12,500,000
|
[32] |
|
|
|
|
|
|
|
Investment cost |
|
12,673,000
|
[1],[31] |
12,443,000
|
[2],[32] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 12,408,000
|
[31] |
$ 12,443,000
|
[32] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | enGene, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-07
|
|
2025-07
|
|
2025-07
|
|
2025-07
|
|
|
|
|
Investment Interest Rate |
[11],[27],[28] |
|
|
6.35%
|
|
|
|
6.35%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
5.00%
|
[7] |
5.00%
|
[11],[27],[28] |
5.00%
|
[7] |
5.00%
|
[11],[27],[28] |
|
|
|
Investment, Interest Rate, Floor |
[11],[27],[28] |
|
|
8.25%
|
|
|
|
8.25%
|
|
|
|
|
Interest Rate and Floor |
[11],[27],[28] |
|
|
6.35%
|
|
|
|
6.35%
|
|
|
|
|
Principal Amount |
|
$ 11,000,000
|
[17],[29],[30] |
$ 7,000,000
|
[27],[28] |
|
|
|
|
|
|
|
Investment cost |
|
10,994,000
|
[1],[17],[29],[30] |
6,858,000
|
[2],[27],[28] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 10,918,000
|
[17],[29],[30] |
$ 6,858,000
|
[27],[28] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Finch Therapeutics Group, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-11
|
|
|
|
2026-11
|
|
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[7] |
4.05%
|
|
|
|
4.05%
|
|
|
|
|
|
|
Investment, Interest Rate, Floor |
[7] |
7.55%
|
|
|
|
7.55%
|
|
|
|
|
|
|
Principal Amount |
[10] |
$ 15,000,000
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[10] |
14,958,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[10] |
$ 14,241,000
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | G1 Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-11
|
|
2026-11
|
|
2026-11
|
|
2026-11
|
|
|
|
|
Investment Interest Rate |
[11],[27] |
|
|
9.86%
|
|
|
|
9.86%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
5.90%
|
[7] |
5.90%
|
[11],[27] |
5.90%
|
[7] |
5.90%
|
[11],[27] |
|
|
|
Investment, Interest Rate, Floor |
|
9.15%
|
[7] |
9.15%
|
[11],[27] |
9.15%
|
[7] |
9.15%
|
[11],[27] |
|
|
|
Interest Rate and Floor |
[11],[27] |
|
|
9.86%
|
|
|
|
9.86%
|
|
|
|
|
Principal Amount |
|
$ 58,125,000
|
[10],[12],[18],[31] |
$ 58,125,000
|
[14],[15],[27],[32],[33] |
|
|
|
|
|
|
|
Investment cost |
|
58,472,000
|
[1],[10],[12],[18],[31] |
57,873,000
|
[2],[14],[15],[27],[32],[33] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 58,006,000
|
[10],[12],[18],[31] |
$ 57,874,000
|
[14],[15],[27],[32],[33] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Geron Corporation | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-10
|
|
2024-10
|
|
2024-10
|
|
2024-10
|
|
|
|
|
Investment Interest Rate |
[11],[27] |
|
|
6.55%
|
|
|
|
6.55%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
5.75%
|
[7] |
5.75%
|
[11],[27] |
5.75%
|
[7] |
5.75%
|
[11],[27] |
|
|
|
Investment, Interest Rate, Floor |
|
9.00%
|
[7] |
9.00%
|
[11],[27] |
9.00%
|
[7] |
9.00%
|
[11],[27] |
|
|
|
Interest Rate and Floor |
[11],[27] |
|
|
6.55%
|
|
|
|
6.55%
|
|
|
|
|
Principal Amount |
|
$ 18,500,000
|
[17],[18],[29] |
$ 32,500,000
|
[27],[33] |
|
|
|
|
|
|
|
Investment cost |
|
19,003,000
|
[1],[17],[18],[29] |
32,704,000
|
[2],[27],[33] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 19,059,000
|
[17],[18],[29] |
$ 32,744,000
|
[27],[33] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Gritstone Bio, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2027-07
|
|
|
|
2027-07
|
|
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[7] |
3.15%
|
|
|
|
3.15%
|
|
|
|
|
|
|
Investment, Interest Rate, Floor |
[7] |
7.15%
|
|
|
|
7.15%
|
|
|
|
|
|
|
Investment, Interest Rate, Paid in Kind |
[7] |
2.00%
|
|
|
|
2.00%
|
|
|
|
|
|
|
Principal Amount |
[9],[10] |
$ 15,037,000
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[9],[10] |
14,989,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[9],[10] |
$ 14,989,000
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Hibercell, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-05
|
|
2025-05
|
|
2025-05
|
|
2025-05
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
4.95%
|
|
|
|
4.95%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
5.40%
|
[7] |
5.40%
|
[11] |
5.40%
|
[7] |
5.40%
|
[11] |
|
|
|
Investment, Interest Rate, Floor |
|
8.65%
|
[7] |
8.65%
|
[11] |
8.65%
|
[7] |
8.65%
|
[11] |
|
|
|
Interest Rate and Floor |
[11] |
|
|
4.95%
|
|
|
|
4.95%
|
|
|
|
|
Principal Amount |
|
$ 17,000,000
|
[17],[31] |
$ 17,000,000
|
[32] |
|
|
|
|
|
|
|
Investment cost |
|
17,244,000
|
[1],[17],[31] |
17,041,000
|
[2],[32] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 17,225,000
|
[17],[31] |
$ 17,014,000
|
[32] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | HilleVax, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2027-05
|
|
|
|
2027-05
|
|
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[7] |
1.05%
|
|
|
|
1.05%
|
|
|
|
|
|
|
Investment, Interest Rate, Floor |
[7] |
4.55%
|
|
|
|
4.55%
|
|
|
|
|
|
|
Investment, Interest Rate, Paid in Kind |
[7] |
2.85%
|
|
|
|
2.85%
|
|
|
|
|
|
|
Principal Amount |
[9],[10],[31] |
$ 4,043,000
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[9],[10],[31] |
4,043,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[9],[10],[31] |
$ 4,044,000
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Iveric Bio Gene Therapy LLC | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2027-08
|
|
|
|
2027-08
|
|
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[7] |
4.00%
|
|
|
|
4.00%
|
|
|
|
|
|
|
Investment, Interest Rate, Floor |
[7] |
8.75%
|
|
|
|
8.75%
|
|
|
|
|
|
|
Principal Amount |
[10],[29] |
$ 24,750,000
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[10],[29] |
24,530,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[10],[29] |
$ 24,531,000
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Humanigen, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
2025-03
|
|
|
|
2025-03
|
|
|
|
|
Investment Interest Rate |
[11],[26],[27] |
|
|
6.75%
|
|
|
|
6.75%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[11],[26],[27] |
|
|
5.50%
|
|
|
|
5.50%
|
|
|
|
|
Investment, Interest Rate, Floor |
[11],[26],[27] |
|
|
8.75%
|
|
|
|
8.75%
|
|
|
|
|
Interest Rate and Floor |
[11],[26],[27] |
|
|
6.75%
|
|
|
|
6.75%
|
|
|
|
|
Principal Amount |
[26],[27] |
|
|
$ 20,000,000
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[26],[27] |
|
|
20,235,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[26],[27] |
|
|
$ 19,985,000
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Kaleido Biosciences, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
2024-01
|
|
|
|
2024-01
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
7.55%
|
|
|
|
7.55%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[11] |
|
|
6.10%
|
|
|
|
6.10%
|
|
|
|
|
Investment, Interest Rate, Floor |
[11] |
|
|
9.35%
|
|
|
|
9.35%
|
|
|
|
|
Interest Rate and Floor |
[11] |
|
|
7.55%
|
|
|
|
7.55%
|
|
|
|
|
Principal Amount |
[33] |
|
|
$ 22,500,000
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[33] |
|
|
23,505,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[33] |
|
|
$ 23,384,000
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Locus Biosciences, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-07
|
|
2025-07
|
|
2025-07
|
|
2025-07
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
4.95%
|
|
|
|
4.95%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
6.10%
|
[7] |
6.10%
|
[11] |
6.10%
|
[7] |
6.10%
|
[11] |
|
|
|
Investment, Interest Rate, Floor |
|
9.35%
|
[7] |
9.35%
|
[11] |
9.35%
|
[7] |
9.35%
|
[11] |
|
|
|
Interest Rate and Floor |
[11] |
|
|
4.95%
|
|
|
|
4.95%
|
|
|
|
|
Principal Amount |
|
$ 8,000,000
|
[31] |
$ 8,000,000
|
[32] |
|
|
|
|
|
|
|
Investment cost |
|
8,084,000
|
[1],[31] |
7,977,000
|
[2],[32] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 8,062,000
|
[31] |
$ 7,900,000
|
[32] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Madrigal Pharmaceutical, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-05
|
|
|
|
2026-05
|
|
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[7] |
3.95%
|
|
|
|
3.95%
|
|
|
|
|
|
|
Investment, Interest Rate, Floor |
[7] |
7.45%
|
|
|
|
7.45%
|
|
|
|
|
|
|
Principal Amount |
[29] |
$ 34,000,000
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[29] |
33,807,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[29] |
$ 33,807,000
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Phathom Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-10
|
|
2026-10
|
|
2026-10
|
|
2026-10
|
|
|
|
|
Investment Interest Rate |
[11],[27] |
|
|
7.50%
|
|
|
|
7.50%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
2.25%
|
[7] |
2.25%
|
[11],[27] |
2.25%
|
[7] |
2.25%
|
[11],[27] |
|
|
|
Investment, Interest Rate, Floor |
|
5.50%
|
[7] |
5.50%
|
[11],[27] |
5.50%
|
[7] |
5.50%
|
[11],[27] |
|
|
|
Investment, Interest Rate, Paid in Kind |
|
3.35%
|
[7] |
3.35%
|
[11],[27] |
3.35%
|
[7] |
3.35%
|
[11],[27] |
|
|
|
Interest Rate and Floor |
[11],[27] |
|
|
7.50%
|
|
|
|
7.50%
|
|
|
|
|
Principal Amount |
|
$ 93,978,000
|
[9],[10],[18],[19],[29],[31] |
$ 87,116,000
|
[15],[20],[21],[27],[32],[33] |
|
|
|
|
|
|
|
Investment cost |
|
93,948,000
|
[1],[9],[10],[18],[19],[29],[31] |
86,075,000
|
[2],[15],[20],[21],[27],[32],[33] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 94,006,000
|
[9],[10],[18],[19],[29],[31] |
$ 86,075,000
|
[15],[20],[21],[27],[32],[33] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Provention Bio, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-09
|
|
|
|
2026-09
|
|
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[7] |
2.70%
|
|
|
|
2.70%
|
|
|
|
|
|
|
Investment, Interest Rate, Floor |
[7] |
8.20%
|
|
|
|
8.20%
|
|
|
|
|
|
|
Principal Amount |
|
$ 25,000,000
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1] |
24,552,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 24,552,000
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Redshift Bioanalytics, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-01
|
|
|
|
2026-01
|
|
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[7] |
4.25%
|
|
|
|
4.25%
|
|
|
|
|
|
|
Investment, Interest Rate, Floor |
[7] |
7.50%
|
|
|
|
7.50%
|
|
|
|
|
|
|
Principal Amount |
[31] |
$ 5,000,000
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[31] |
4,936,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[31] |
$ 4,935,000
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Scynexis, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-03
|
|
2025-03
|
|
2025-03
|
|
2025-03
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
3.95%
|
|
|
|
3.95%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
5.80%
|
[7] |
5.80%
|
[11] |
5.80%
|
[7] |
5.80%
|
[11] |
|
|
|
Investment, Interest Rate, Floor |
|
9.05%
|
[7] |
9.05%
|
[11] |
9.05%
|
[7] |
9.05%
|
[11] |
|
|
|
Interest Rate and Floor |
[11] |
|
|
3.95%
|
|
|
|
3.95%
|
|
|
|
|
Principal Amount |
|
$ 18,667,000
|
[17],[18] |
$ 16,000,000
|
|
|
|
|
|
|
|
|
Investment cost |
|
18,592,000
|
[1],[17],[18] |
15,826,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 18,524,000
|
[17],[18] |
$ 15,778,000
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Seres Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-10
|
|
2023-11
|
|
2024-10
|
|
2023-11
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
4.85%
|
|
|
|
4.85%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
6.40%
|
[7] |
4.40%
|
[11] |
6.40%
|
[7] |
4.40%
|
[11] |
|
|
|
Investment, Interest Rate, Floor |
|
9.65%
|
[7] |
9.65%
|
[11] |
9.65%
|
[7] |
9.65%
|
[11] |
|
|
|
Interest Rate and Floor |
[11] |
|
|
4.85%
|
|
|
|
4.85%
|
|
|
|
|
Principal Amount |
|
$ 37,500,000
|
[17],[18] |
$ 24,051,000
|
|
|
|
|
|
|
|
|
Investment cost |
|
38,509,000
|
[1],[17],[18] |
24,777,000
|
[2] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 38,657,000
|
[17],[18] |
$ 25,183,000
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Syndax Pharmaceutics Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
2024-04
|
|
|
|
2024-04
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
4.99%
|
|
|
|
4.99%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[11] |
|
|
6.00%
|
|
|
|
6.00%
|
|
|
|
|
Investment, Interest Rate, Floor |
[11] |
|
|
9.25%
|
|
|
|
9.25%
|
|
|
|
|
Interest Rate and Floor |
[11] |
|
|
4.99%
|
|
|
|
4.99%
|
|
|
|
|
Principal Amount |
[15],[33] |
|
|
$ 20,000,000
|
|
|
|
|
|
|
|
|
Investment cost |
[2],[15],[33] |
|
|
20,646,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[15],[33] |
|
|
$ 20,653,000
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Tarsus Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2027-02
|
|
|
|
2027-02
|
|
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[7] |
5.20%
|
|
|
|
5.20%
|
|
|
|
|
|
|
Investment, Interest Rate, Floor |
[7] |
8.45%
|
|
|
|
8.45%
|
|
|
|
|
|
|
Principal Amount |
[10],[17],[29] |
$ 8,250,000
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[10],[17],[29] |
8,255,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[10],[17],[29] |
$ 8,388,000
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | TG Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-01
|
|
2026-01
|
|
2026-01
|
|
2026-01
|
|
|
|
|
Investment Interest Rate |
[11],[27] |
|
|
5.95%
|
|
|
|
5.95%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
2.15%
|
[7] |
2.15%
|
[11],[27] |
2.15%
|
[7] |
2.15%
|
[11],[27] |
|
|
|
Investment, Interest Rate, Floor |
|
5.40%
|
[7] |
5.40%
|
[11],[27] |
5.40%
|
[7] |
5.40%
|
[11],[27] |
|
|
|
Investment, Interest Rate, Paid in Kind |
[7] |
3.45%
|
|
|
|
3.45%
|
|
|
|
|
|
|
Interest Rate and Floor |
[11],[27] |
|
|
5.95%
|
|
|
|
5.95%
|
|
|
|
|
Principal Amount |
|
$ 47,567,000
|
[9],[12],[18],[29] |
$ 51,450,000
|
[27] |
|
|
|
|
|
|
|
Investment cost |
|
47,267,000
|
[1],[9],[12],[18],[29] |
50,470,000
|
[2],[27] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 47,137,000
|
[9],[12],[18],[29] |
$ 50,470,000
|
[27] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Uni Qure B V | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2025-12
|
|
2025-12
|
|
2025-12
|
|
2025-12
|
|
|
|
|
Investment Interest Rate |
[11],[27],[28] |
|
|
7.28%
|
|
|
|
7.28%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
4.70%
|
[7] |
4.70%
|
[11],[27],[28] |
4.70%
|
[7] |
4.70%
|
[11],[27],[28] |
|
|
|
Investment, Interest Rate, Floor |
|
7.95%
|
[7] |
7.95%
|
[11],[27],[28] |
7.95%
|
[7] |
7.95%
|
[11],[27],[28] |
|
|
|
Interest Rate and Floor |
[11],[27],[28] |
|
|
7.28%
|
|
|
|
7.28%
|
|
|
|
|
Principal Amount |
|
$ 70,000,000
|
[12],[18],[19],[29],[30] |
$ 77,500,000
|
[14],[21],[27],[28],[33] |
|
|
|
|
|
|
|
Investment cost |
|
72,015,000
|
[1],[12],[18],[19],[29],[30] |
78,755,000
|
[2],[14],[21],[27],[28],[33] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 73,205,000
|
[12],[18],[19],[29],[30] |
$ 78,755,000
|
[14],[21],[27],[28],[33] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Unity Biotechnology Inc | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-08
|
|
2024-08
|
|
2024-08
|
|
2024-08
|
|
|
|
|
Investment Interest Rate |
[11],[26] |
|
|
6.25%
|
|
|
|
6.25%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
6.10%
|
[7] |
6.10%
|
[11],[26] |
6.10%
|
[7] |
6.10%
|
[11],[26] |
|
|
|
Investment, Interest Rate, Floor |
|
9.35%
|
[7] |
9.35%
|
[11],[26] |
9.35%
|
[7] |
9.35%
|
[11],[26] |
|
|
|
Interest Rate and Floor |
[11],[26] |
|
|
6.25%
|
|
|
|
6.25%
|
|
|
|
|
Principal Amount |
|
$ 20,000,000
|
[17] |
$ 22,701,000
|
[26] |
|
|
|
|
|
|
|
Investment cost |
|
20,990,000
|
[1],[17] |
23,293,000
|
[2],[26] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 20,844,000
|
[17] |
$ 23,627,000
|
[26] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Valo Health L L C | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-05
|
|
2024-05
|
|
2024-05
|
|
2024-05
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
3.85%
|
|
|
|
3.85%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
6.45%
|
[7] |
6.45%
|
[11] |
6.45%
|
[7] |
6.45%
|
[11] |
|
|
|
Investment, Interest Rate, Floor |
|
9.70%
|
[7] |
9.70%
|
[11] |
9.70%
|
[7] |
9.70%
|
[11] |
|
|
|
Interest Rate and Floor |
[11] |
|
|
3.85%
|
|
|
|
3.85%
|
|
|
|
|
Principal Amount |
|
$ 9,583,000
|
[12],[17] |
$ 11,500,000
|
[14] |
|
|
|
|
|
|
|
Investment cost |
|
9,805,000
|
[1],[12],[17] |
11,547,000
|
[2],[14] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 9,760,000
|
[12],[17] |
$ 11,492,000
|
[14] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Viridian Therapeutics Inc | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2026-10
|
|
|
|
2026-10
|
|
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[7] |
4.20%
|
|
|
|
4.20%
|
|
|
|
|
|
|
Investment, Interest Rate, Floor |
[7] |
7.45%
|
|
|
|
7.45%
|
|
|
|
|
|
|
Principal Amount |
[10],[17],[29] |
$ 2,000,000
|
|
|
|
|
|
|
|
|
|
|
Investment cost |
[1],[10],[17],[29] |
2,004,000
|
|
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
[10],[17],[29] |
$ 1,969,000
|
|
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | X Four Pharmaceuticals Inc | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
2024-07
|
|
2024-07
|
|
2024-07
|
|
2024-07
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
8.80%
|
|
|
|
8.80%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
|
3.75%
|
[7] |
3.75%
|
[11] |
3.75%
|
[7] |
3.75%
|
[11] |
|
|
|
Investment, Interest Rate, Floor |
|
8.75%
|
[7] |
8.75%
|
[11] |
8.75%
|
[7] |
8.75%
|
[11] |
|
|
|
Interest Rate and Floor |
[11] |
|
|
8.80%
|
|
|
|
8.80%
|
|
|
|
|
Principal Amount |
|
$ 32,500,000
|
[12],[17],[18] |
$ 32,500,000
|
[14],[33] |
|
|
|
|
|
|
|
Investment cost |
|
33,464,000
|
[1],[12],[17],[18] |
34,140,000
|
[2],[14],[33] |
|
|
|
|
|
|
|
Investments at Fair Value |
|
$ 33,291,000
|
[12],[17],[18] |
$ 34,085,000
|
[14],[33] |
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Yumanity Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
2024-01
|
|
|
|
2024-01
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
5.92%
|
|
|
|
5.92%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[11] |
|
|
4.00%
|
|
|
|
4.00%
|
|
|
|
|
Investment, Interest Rate, Floor |
[11] |
|
|
8.75%
|
|
|
|
8.75%
|
|
|
|
|
Interest Rate and Floor |
[11] |
|
|
5.92%
|
|
|
|
5.92%
|
|
|
|
|
Principal Amount |
|
|
|
$ 12,732,000
|
|
|
|
|
|
|
|
|
Investment cost |
[2] |
|
|
13,256,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
|
|
$ 13,187,000
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Center for Breakthrough Medicines Holdings, LLC [Member] | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Maturity Date |
|
|
|
2023-05
|
|
|
|
2023-05
|
|
|
|
|
Investment Interest Rate |
[11] |
|
|
7.50%
|
|
|
|
7.50%
|
|
|
|
|
Investment, Basis Spread, Variable Rate |
[11] |
|
|
5.50%
|
|
|
|
5.50%
|
|
|
|
|
Investment, Interest Rate, Floor |
[11] |
|
|
8.75%
|
|
|
|
8.75%
|
|
|
|
|
Interest Rate and Floor |
[11] |
|
|
7.50%
|
|
|
|
7.50%
|
|
|
|
|
Principal Amount |
|
|
|
$ 5,000,000
|
|
|
|
|
|
|
|
|
Investment cost |
[4] |
|
|
5,005,000
|
|
|
|
|
|
|
|
|
Investments at Fair Value |
|
|
|
$ 5,005,000
|
|
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Floor Rate | enGene, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment, Interest Rate, Floor |
[7] |
8.25%
|
|
|
|
8.25%
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Exit Fee | Chemocentryx, Inc. | Debt Investments Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Interest Rate |
[7] |
6.25%
|
|
|
|
6.25%
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
6.25%
|
|
|
|
6.25%
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Exit Fee | Chemocentryx, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Interest Rate |
[7] |
7.15%
|
|
|
|
7.15%
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
7.15%
|
|
|
|
7.15%
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Exit Fee | Nabriva Therapeutics | Debt Investments Under 1 Year Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Interest Rate |
[7] |
9.95%
|
|
|
|
9.95%
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
9.95%
|
|
|
|
9.95%
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Exit Fee | Akero Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Interest Rate |
[7] |
5.85%
|
|
|
|
5.85%
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
5.85%
|
|
|
|
5.85%
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Exit Fee | Alladapt Immunotherapeutics Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Interest Rate |
[7] |
5.30%
|
|
|
|
5.30%
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
5.30%
|
|
|
|
5.30%
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Exit Fee | Aldeyra Therapeutics, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Interest Rate |
[7] |
6.95%
|
|
|
|
6.95%
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
6.95%
|
|
|
|
6.95%
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Exit Fee | Applied Genetic Technologies Corporation | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Interest Rate |
|
6.95%
|
[7] |
6.95%
|
[11] |
6.95%
|
[7] |
6.95%
|
[11] |
|
|
|
Interest Rate and Floor |
|
6.95%
|
[7] |
6.95%
|
[11] |
6.95%
|
[7] |
6.95%
|
[11] |
|
|
|
Drug Discovery & Development | Senior Secured | Exit Fee | ATAI Life Sciences N.V. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Interest Rate |
[7] |
6.95%
|
|
|
|
6.95%
|
|
|
|
|
|
|
Interest Rate and Floor |
[7] |
6.95%
|
|
|
|
6.95%
|
|
|
|
|
|
|
Drug Discovery & Development | Senior Secured | Exit Fee | Aveo Pharmaceuticals, Inc. | Debt Investments 1-5 Years Maturity |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Holdings [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
Investment Interest Rate |
|
6.95%
|
[7] |
6.95%
|
[11] |
6.95%
|
[7] |
6.95%
|
[11] |
|
|
|
|